Acer Therapeutics Inc (NASDAQ:ACER)
| 0.87 BATS BZX Real-Time Price As of 3:01pm ET |  -0.0037 / -0.42%Today’s Change | 0.65 Today|||52-Week Range 4.56 | -65.34% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Pharmaceuticals: Major | MARKET CAP $22.0M |
Company Description
Acer Therapeutics, Inc. is a pharmaceutical company, which engages in the acquisition, development, and commercialization of therapies for medical needs. Its product pipeline includes Olpruva, Edsivo, and ACER-801. Olpruva is used for the treatment of urea cycle disorders. Edsivo is a type of celiprolol used in treating Vascular Ehlers-Danlos syndrome. ACER-001 treats menopausal related Vasomotor symptoms. The company was founded by Chris Schelling in December 2013 and is headquartered in Newton, MA.
Contact Information
Acer Therapeutics, Inc. One Gateway Center Newton Massachusetts 02458 |
Employees
Shareholders
| Individual stakeholders | 29.35% |
| Mutual fund holders | 2.59% |
| Other institutional | 19.22% |
Top Executives
| Christopher Schelling | President, Chief Executive Officer & Director |
| Tanya Hayden | Chief Operating Officer |
| Harry S. Palmin | Chief Financial Officer |
| Adrian Quartel | Chief Medical Officer |
| John M. Klopp | Chief Technical Officer |
